Table 1. Characteristics of the included studies.
| Study | Year | Clinical trial | Patients (n) | Male (%) (Arm-1 vs Arm-2) | Median age (Years) | Treatment | Jadad score |
|---|---|---|---|---|---|---|---|
| Yamada et al. [7] | 2015 | Phase III | 685 | 75.5% vs 73.1% | 65 vs 65 | Arm-1: 80–120 mg/day S-1 for 2 weeks with 100 mg/m2 oxaliplatin on day 1, every 3 weeksArm-2: S-1 for 3 weeks with 60 mg/m2 cisplatin on day 8, every 5 weeks | 3 |
| Kim et al. [9] | 2014 | Phase II | 77 | 67.0% vs 74.0% | 58 vs 56 | Arm-1: 35 mg/m2 docetaxel weekly on days 1 and 8 and 120 mg/m2 oxaliplatin on day 1, every 3 weeksArm-2: 35 mg/m2 docetaxel weekly on days 1 and 8 and 60 mg/m2 on day 1, every 3 weeks | 2 |
| Al-Batran et al. [10] | 2008 | Phase III | 220 | 57.1% vs 75.0% | 64 vs 64 | Arm-1: oxaliplatin 85 mg/m2 day 1, 5-FU 2600 mg/m2 24 h-c.i. day 1, FA 200 mg/m2 day 1, every 2 weeksArm-2: cisplatin 50 mg/m2 day 1, 5-FU, every 2 weeks | 2 |
| Cunningham et al. (1) [11] | 2008 | Phase III | 508 | 81.3% vs 81.1% | 61 vs 65 | Arm-1: epirubicin 60 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, 5-FU c.i. 200 mg/m2 daily, every 3 weeksArm-2: epirubicin 60 mg/m2 day 1, cisplatin 50 mg/m2 day 1, 5-FU c.i. 200 mg/m2, every 3 weeks | 3 |
| Cunningham et al. (2) [11] | 2008 | Phase III | 494 | 82.8% vs 80.5% | 62 vs 64 | Arm-1: epirubicin 60 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, capecitabine 625 mg/m2 × 2 daily, every 3 weeksArm-2: epirubicin 50 mg/m2 day 1, cisplatin 50 mg/m2 day 1, capecitabine 625 mg/m2 × 2 daily, every 3 weeks | 3 |
| Popov et al. [12] | 2008 | Phase II | 62 | 66.7% vs 72.2% | 57 vs 55 | Arm-1: oxaliplatin 85 mg/m2 day 1, 5-FU bolus 400 mg/m2 day 1, 2, 5-FU 600 mg/m2 22 h c.i. day 1, 2, FA = 200 mg/m2 d1, 2, every 2 weeksArm-2: cisplatin 50 mg/m2 day 1,5-FU bolus 400 mg/m2 day 1, 2, 5-FU 600 mg/m2 22 h c.i. day 1, 2, FA = 200 mg/m2 day 1, 2, every 2 weeks | 2 |
c.i. Continuous infusion; 5-FU 5-fluorouracil; FA folinic acid.